Medical Stocks List → The ONE AI sSock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) This page shows information about the 50 largest medical stocks including Eli Lilly and Company, Novo Nordisk A/S, UnitedHealth Group, and Johnson & Johnson. Learn more about medical stocks. #1 - Eli Lilly and CompanyNYSE:LLYStock Price: $762.66 (+$8.49)Market Cap: $716.59 billionP/E Ratio: 131.5Dividend Yield: 0.69%Consensus Rating: Moderate Buy (16 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $689.52 (-9.6% Upside)Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Eli Lilly and Company Stock Pros Eli Lilly and Company has a diverse portfolio of pharmaceutical products catering to various medical needs, including diabetes, oncology, rheumatoid arthritis, and more. The company has a strong history of innovation and research, consistently developing new drugs and treatments to address evolving healthcare challenges. Recent collaborations with reputable pharmaceutical companies indicate potential for future growth and expansion in the industry. Cons Market competition in the pharmaceutical industry is intense, leading to potential challenges in maintaining market share and pricing power. Regulatory uncertainties and changes in healthcare policies can impact Eli Lilly's operations and profitability. Dependency on a few key products for a significant portion of revenue poses risks in case of patent expirations or market shifts. #2 - Novo Nordisk A/SNYSE:NVOStock Price: $132.89 (+$0.52)Market Cap: $594.01 billionP/E Ratio: 49.1Dividend Yield: 0.47%Consensus Rating: Moderate Buy (6 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $121.25 (-8.8% Upside)Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Novo Nordisk A/S Stock Pros Novo Nordisk controls a significant portion of the diabetes care market, including both GLP-1 and insulin products, providing a strong market position in a lucrative industry. The company has a diverse product portfolio, including treatments for rare diseases such as hemophilia, sickle cell disease, and various growth disorders, offering revenue streams from multiple sources. Novo Nordisk has an extensive pipeline of drug candidates, with several in Phase 3, indicating potential for future growth and innovation. Cons Novo Nordisk's stock price is trading at a relatively high P/E ratio compared to its peers, which may deter some value-oriented investors. The healthcare sector average dividend yield is higher than Novo Nordisk's, indicating lower cash payouts to investors compared to other healthcare companies. While Novo Nordisk has shown strong historical returns, past performance is not always indicative of future results, and market conditions can change. #3 - UnitedHealth GroupNYSE:UNHStock Price: $487.08 (-$3.74)Market Cap: $452.50 billionP/E Ratio: 20.4Dividend Yield: 1.53%Consensus Rating: Moderate Buy (15 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $579.33 (18.9% Upside)UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of UnitedHealth Group Stock Pros UnitedHealth Group operates through multiple segments, providing diversified exposure to the healthcare industry, which can help mitigate risks associated with a single sector. The company offers a wide range of health benefit plans and services catering to various demographics, including older individuals and those in need of Medicaid, which can lead to stable revenue streams. UnitedHealth Group has a strong presence in the healthcare market, allowing it to negotiate favorable terms with healthcare providers and potentially improve profitability. Cons Regulatory changes in the healthcare industry could impact UnitedHealth Group's operations and profitability, leading to uncertainties for investors. The competitive landscape in the healthcare sector is intense, with other major players vying for market share, potentially affecting UnitedHealth Group's growth prospects. Fluctuations in healthcare policies and government interventions can create challenges for UnitedHealth Group's business strategies and financial performance. #4 - Johnson & JohnsonNYSE:JNJStock Price: $156.77 (-$1.41)Market Cap: $381.18 billionP/E Ratio: 11.4Dividend Yield: 3.01%Consensus Rating: Hold (5 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $177.31 (13.1% Upside)Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Johnson & Johnson Stock Pros Johnson & Johnson has a diverse range of healthcare products under well-known brands like NEUTROGENA, LISTERINE, and TYLENOL, providing stability and potential for growth in various segments of the healthcare industry. The company has a strong track record of research, development, and innovation, consistently introducing new products to meet evolving consumer needs and maintain competitiveness in the market. Johnson & Johnson's stock price has shown resilience and growth, reflecting investor confidence in the company's ability to navigate challenges and deliver value over time. Cons Johnson & Johnson faces ongoing legal challenges and lawsuits related to various products, which could lead to financial penalties, reputational damage, and potential disruptions to business operations. The healthcare industry is subject to regulatory changes, pricing pressures, and intense competition, posing risks to Johnson & Johnson's profitability and market position. Concerns about potential product recalls or safety issues could impact consumer trust and brand reputation, affecting sales and long-term growth prospects. #5 - AbbVieNYSE:ABBVStock Price: $178.53 (+$0.65)Market Cap: $314.22 billionP/E Ratio: 65.4Dividend Yield: 3.49%Consensus Rating: Moderate Buy (9 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $175.36 (-1.8% Upside)AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine with or without aura in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of AbbVie Stock Pros AbbVie offers a diverse portfolio of pharmaceutical products, including innovative treatments like Skyrizi for plaque psoriasis and Rinvoq for various inflammatory conditions, providing potential for revenue growth. The company has a strong pipeline of drugs in development, such as Venclexta/Venclyxto for hematological malignancies, indicating future potential for expansion and market competitiveness. AbbVie's collaboration agreements with reputable companies like Genentech and Janssen Biotech demonstrate strategic partnerships that can lead to new breakthrough therapies and increased market presence. Cons AbbVie faces risks associated with patent expirations on key products like Humira, which could lead to revenue declines and increased competition from generic alternatives, impacting profitability. The pharmaceutical industry is subject to regulatory challenges and pricing pressures, potentially affecting AbbVie's ability to maintain margins and sustain growth in a highly competitive market. Concerns over potential litigation or regulatory issues related to drug safety or marketing practices could pose reputational risks for AbbVie and impact investor confidence in the company's governance and compliance standards. #6 - Merck & Co., Inc.NYSE:MRKStock Price: $121.44 (-$0.08)Market Cap: $307.77 billionP/E Ratio: 867.4Dividend Yield: 2.53%Consensus Rating: Moderate Buy (10 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $129.14 (6.3% Upside)Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Merck & Co., Inc. Stock Pros Merck's strong product portfolio includes innovative pharmaceuticals in areas such as oncology, immunology, and cardiovascular health, providing potential for steady revenue growth. Recent insider selling activities indicate confidence in the company's performance and future prospects, which can be a positive signal for investors. Analysts have given Merck a favorable rating, with a majority recommending buying or holding the stock, suggesting a positive outlook for its financial performance. Cons Market volatility and regulatory challenges in the pharmaceutical industry can impact Merck's stock performance, leading to potential fluctuations in share prices. Competition from other pharmaceutical companies and generic drug manufacturers may pose a threat to Merck's market share and revenue growth in the long run. External factors such as changes in healthcare policies or global economic conditions could affect Merck's profitability and stock valuation unpredictably. Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. #7 - Thermo Fisher ScientificNYSE:TMOStock Price: $580.23 (-$3.92)Market Cap: $222.74 billionP/E Ratio: 37.6Dividend Yield: 0.27%Consensus Rating: Moderate Buy (10 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $599.00 (3.2% Upside)Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Thermo Fisher Scientific Stock Pros Thermo Fisher Scientific Inc. has a strong presence in the life sciences industry, offering a wide range of solutions and products for various markets globally. The company's consistent focus on innovation and research & development keeps it at the forefront of technological advancements in the sector, ensuring competitiveness. Thermo Fisher Scientific Inc.'s diverse product portfolio, including analytical instruments, specialty diagnostics, and laboratory products, provides stability and multiple revenue streams. Cons Market competition in the life sciences industry is intense, which could potentially impact Thermo Fisher Scientific Inc.'s market share and profitability. External factors such as regulatory changes or disruptions in the supply chain could pose risks to the company's operations and financial performance. Investing in Thermo Fisher Scientific Inc. may require a long-term perspective, as short-term market fluctuations could affect stock prices despite the company's strong fundamentals. #8 - NovartisNYSE:NVSStock Price: $95.92 (-$1.35)Market Cap: $206.17 billionP/E Ratio: 13.4Dividend Yield: 2.52%Consensus Rating: Hold (1 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $104.33 (8.8% Upside)Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. It offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Novartis Stock Pros Novartis has been actively developing and commercializing innovative healthcare products, focusing on various therapeutic areas such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology. This diverse portfolio can lead to sustained revenue growth and market expansion. Novartis has entered into strategic collaborations, like the one with Alnylam Pharmaceuticals for inclisiran, a therapy to reduce LDL cholesterol. Such partnerships can enhance Novartis' product offerings and potentially increase market share. Recent reports indicate that several large institutional investors have been increasing their stakes in Novartis, signaling confidence in the company's future performance. This investor interest could reflect positively on the stock price and overall market sentiment. Cons Despite the positive analyst ratings, there are still some hold recommendations on Novartis stock, indicating potential risks or uncertainties in the company's future performance. Investors should carefully consider these factors before making investment decisions. The pharmaceutical industry is highly regulated and subject to market volatility, patent expirations, and competition from generic drugs. These factors can impact Novartis' revenue streams and profitability in the long run. While institutional investors have been increasing their stakes in Novartis, the high ownership concentration by a few large investors may pose risks in terms of market influence and potential sell-offs that could affect stock prices unpredictably. #9 - AstraZenecaNASDAQ:AZNStock Price: $65.85 (-$0.46)Market Cap: $205.59 billionP/E Ratio: 34.3Dividend Yield: 2.91%Consensus Rating: Hold (3 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $80.00 (21.5% Upside)AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of AstraZeneca Stock Pros AstraZeneca has a diverse portfolio of marketed products including Tagrisso, Imfinzi, Lynparza, and Farxiga, catering to various medical needs such as oncology, respiratory, and cardiovascular diseases. The company has shown consistent revenue growth, with a net margin of 13.00% and a return on equity of 30.19%, indicating strong financial performance. AstraZeneca recently increased its dividend payout, offering investors a higher yield of 2.3%, which can be attractive for income-focused investors. Cons Recent analyst reports have issued mixed ratings on AstraZeneca, with some firms downgrading the stock to a "sell" or "hold" rating, indicating potential concerns about future performance. The company faces competition in the pharmaceutical industry, which could impact market share and pricing of its products, leading to potential revenue challenges. Market volatility and regulatory changes in the healthcare sector can affect AstraZeneca's operations and financial results, posing risks to investors. #10 - Abbott LaboratoriesNYSE:ABTStock Price: $112.44 (-$3.05)Market Cap: $200.40 billionP/E Ratio: 34.5Dividend Yield: 1.90%Consensus Rating: Moderate Buy (9 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $120.00 (6.7% Upside)Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Abbott Laboratories Stock Pros Abbott Laboratories operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices, providing diversification in its product offerings. The company has a strong history of developing and selling health care products globally, showcasing its expertise and market presence. Recent insider selling of company stock worth $8,071,298 could indicate confidence in the company's future performance. Cons Abbott Laboratories faces competition in the pharmaceutical and healthcare equipment industry, which could impact its market share and profitability. Market volatility and regulatory changes in the healthcare sector may pose risks to Abbott Laboratories' financial performance. Investors should consider the current stock price and valuation metrics to assess the potential for future returns and risks associated with investing in the company. #11 - PfizerNYSE:PFEStock Price: $27.74 (-$0.20)Market Cap: $158.21 billionP/E Ratio: 77.1Dividend Yield: 6.01%Consensus Rating: Hold (6 Buy Ratings, 10 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $36.88 (32.9% Upside)Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Pfizer Stock Pros Pfizer Inc. has a diverse portfolio of biopharmaceutical products, including vaccines and medicines in various therapeutic areas, providing a wide revenue stream. The company has been actively involved in COVID-19 prevention and treatment, with products like Comirnaty and Paxlovid, showcasing its commitment to addressing global health challenges. Pfizer's collaboration agreements with key players like BioNTech SE for mRNA products indicate strategic partnerships that could lead to innovative developments and market advantages. Cons The pharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact Pfizer's product development and market performance. Market volatility and global economic uncertainties may affect Pfizer's financial performance and stock price, leading to potential investment risks. Concerns about patent expirations for key products in Pfizer's portfolio could lead to revenue declines and increased competition from generic alternatives. #12 - AmgenNASDAQ:AMGNStock Price: $270.90 (+$2.03)Market Cap: $144.09 billionP/E Ratio: 21.7Dividend Yield: 3.35%Consensus Rating: Hold (9 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $295.30 (9.0% Upside)Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Amgen Stock Pros Amgen's diverse portfolio of products, including Enbrel, Prolia, and Repatha, cater to a wide range of medical conditions, providing revenue stability. Strong research and development capabilities leading to innovative therapies like KYPROLIS for multiple myeloma, enhancing growth potential. Collaboration agreements with key partners like AstraZeneca and Novartis for product development and commercialization, expanding market reach. Cons Increasing competition in the biotechnology industry may impact market share and pricing strategies for Amgen's products. Regulatory challenges and uncertainties related to drug approvals and pricing could affect revenue streams and profitability. Dependency on a few key products for a significant portion of revenue, exposing the company to risks of market fluctuations and patent expirations. #13 - Intuitive SurgicalNASDAQ:ISRGStock Price: $392.62 (-$3.66)Market Cap: $140.46 billionP/E Ratio: 78.1Consensus Rating: Moderate Buy (16 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $371.60 (-5.4% Upside)Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. The company was incorporated in 1995 and is headquartered in Sunnyvale, California. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Intuitive Surgical Stock Pros Intuitive Surgical, Inc. develops and manufactures products that enable physicians to enhance the quality of minimally invasive care, which is a growing trend in healthcare due to its benefits of faster recovery times and reduced complications. The company offers the da Vinci Surgical System, a leading robotic surgical platform that allows for precise and minimally invasive surgeries, attracting a wide range of healthcare providers looking to offer advanced treatment options. Intuitive Surgical's Ion endoluminal system expands its commercial offerings beyond surgery into diagnostic procedures, tapping into the increasing demand for minimally invasive biopsies and diagnostic techniques. Cons Intuitive Surgical, Inc. operates in a highly competitive market with other medical technology companies constantly innovating, which could pose challenges in maintaining market share and pricing power. The reliance on the da Vinci Surgical System for a significant portion of its revenue makes Intuitive Surgical vulnerable to any potential regulatory changes or technological disruptions that could impact the adoption of robotic surgery systems. Investing in medical technology companies like Intuitive Surgical carries inherent risks related to regulatory approvals, product recalls, and potential litigation, which could affect the company's financial performance and reputation. #14 - StrykerNYSE:SYKStock Price: $354.08 (+$1.85)Market Cap: $133.83 billionP/E Ratio: 42.9Dividend Yield: 0.91%Consensus Rating: Moderate Buy (11 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $331.52 (-6.4% Upside)Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Stryker Stock Pros Stryker Co. has a strong presence in the medical technology industry, offering a wide range of products used in various medical specialties. The company operates through segments like MedSurg and Neurotechnology, and Orthopaedics and Spine, providing diversified revenue streams. Recent institutional investments in Stryker Co., such as Banque Pictet & Cie SA increasing its stake, indicate confidence in the company's growth potential. Cons While Stryker Co. has a strong market presence, the competitive landscape in the medical technology industry is intense, leading to potential challenges in maintaining market share. Fluctuations in healthcare policies and regulations could impact Stryker Co.'s operations and financial performance, posing risks to investors. Recent insider selling activities, such as Director Ronda E. Stryker selling a significant number of shares, may raise concerns about the company's future prospects. #15 - SanofiNASDAQ:SNYStock Price: $47.83 (-$0.46)Market Cap: $122.15 billionP/E Ratio: 20.3Dividend Yield: 2.85%Consensus Rating: Hold (4 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $57.50 (20.2% Upside)Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Sanofi Stock Pros Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions globally, providing a diverse revenue stream. The company offers a range of specialty care products, including DUPIXENT, which has shown significant growth potential in treating various conditions. Sanofi has collaborations with multiple companies for the development of novel treatments, expanding its product pipeline and potential for future revenue growth. Cons Sanofi faces competition in the pharmaceutical industry, which could impact market share and profitability. The healthcare sector is subject to regulatory changes and pricing pressures, affecting the company's revenue and margins. Ongoing research and development costs for new therapies may lead to short-term financial strain on the company. #16 - Elevance HealthNYSE:ELVStock Price: $511.31 (-$1.77)Market Cap: $119.39 billionP/E Ratio: 20.3Dividend Yield: 1.27%Consensus Rating: Moderate Buy (9 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $569.36 (11.4% Upside)Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.#17 - MedtronicNYSE:MDTStock Price: $83.67 (+$0.10)Market Cap: $110.97 billionP/E Ratio: 26.6Dividend Yield: 3.30%Consensus Rating: Hold (6 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $94.91 (13.4% Upside)Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Medtronic Stock Pros Medtronic plc has been consistently introducing innovative medical devices, such as the latest versions of pacemakers and insulin pumps, which have shown promising results in improving patient outcomes. The company's strong financial performance and steady revenue growth make it an attractive investment option for those seeking stability and potential returns. Medtronic plc's global presence and diversified product portfolio reduce its dependency on any single market or product, providing a level of resilience against market fluctuations. Cons Market competition in the medical device industry is intense, leading to pricing pressures and potential challenges in maintaining profit margins for companies like Medtronic plc. Regulatory changes and uncertainties in healthcare policies could impact Medtronic plc's operations and profitability, creating risks for investors in the sector. Fluctuations in currency exchange rates may expose Medtronic plc to foreign exchange risks, affecting its financial performance and investor returns. #18 - Regeneron PharmaceuticalsNASDAQ:REGNStock Price: $959.92 (-$4.55)Market Cap: $105.86 billionP/E Ratio: 27.6Consensus Rating: Moderate Buy (19 Buy Ratings, 5 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $959.09 (-0.1% Upside)Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Regeneron Pharmaceuticals Stock Pros Regeneron Pharmaceuticals has a strong product portfolio, including EYLEA injection for various eye diseases, which has shown significant efficacy in treating these conditions. The company has received positive ratings from Wall Street analysts, with a majority of analysts giving it a "buy" or "outperform" rating, indicating confidence in its growth potential. Recent financial reports show that institutional investors and hedge funds have been increasing their holdings in Regeneron Pharmaceuticals, signaling confidence in the company's future performance. Cons Regeneron Pharmaceuticals faces competition from other biopharmaceutical companies in the market, which could impact its market share and revenue growth. The biopharmaceutical industry is subject to regulatory challenges and uncertainties, which could affect the company's ability to bring new products to market and generate revenue. Market analysts have identified potential risks associated with investing in Regeneron Pharmaceuticals, such as market volatility and changes in healthcare policies that could impact the company's financial performance. #19 - Bristol-Myers SquibbNYSE:BMYStock Price: $51.59 (-$0.75)Market Cap: $105.84 billionP/E Ratio: 13.4Dividend Yield: 4.59%Consensus Rating: Hold (3 Buy Ratings, 15 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $61.12 (18.5% Upside)Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New York. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Bristol-Myers Squibb Stock Pros Bristol-Myers Squibb offers a diverse range of biopharmaceutical products targeting various diseases, providing a broad revenue base. The company's product portfolio includes innovative treatments like Opdivo for multiple anti-cancer indications, which have shown promising results in clinical trials. Recent product launches such as Abecma for relapsed or refractory multiple myeloma demonstrate Bristol-Myers Squibb's commitment to developing cutting-edge therapies. Cons The pharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact Bristol-Myers Squibb's product development and market access. Risks associated with clinical trials and drug approvals may lead to setbacks in the company's pipeline, affecting future revenue streams. Dependency on key products like Opdivo for a significant portion of revenue poses concentration risk if these products face unexpected competition or patent expirations. #20 - Vertex PharmaceuticalsNASDAQ:VRTXStock Price: $411.38 (+$3.69)Market Cap: $105.31 billionP/E Ratio: 29.6Consensus Rating: Hold (12 Buy Ratings, 7 Hold Ratings, 3 Sell Ratings)Consensus Price Target: $417.27 (1.4% Upside)Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Vertex Pharmaceuticals Stock Pros Vertex Pharmaceuticals has a strong market capitalization of $106.38 billion, indicating stability and potential for growth. The company's stock price has shown resilience, with a 12-month high of $448.40, suggesting positive investor sentiment. Vertex Pharmaceuticals has a low debt-to-equity ratio of 0.02, signifying a healthy financial structure. Cons Vertex Pharmaceuticals' stock price experienced a decline during mid-day trading, reaching $411.85, which may indicate short-term volatility. Chairman Jeffrey M. Leiden sold a significant number of shares, which could raise concerns about insider sentiment or future company performance. While the company has shown growth, increased competition in the pharmaceutical industry could pose challenges to Vertex Pharmaceuticals' market position. #21 - The Cigna GroupNYSE:CIStock Price: $352.63 (+$0.58)Market Cap: $102.92 billionP/E Ratio: 20.3Dividend Yield: 1.59%Consensus Rating: Moderate Buy (12 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $361.87 (2.6% Upside)The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of The Cigna Group Stock Pros The Cigna Group has shown consistent growth in institutional investor ownership, indicating confidence in the company's future prospects. The company's Evernorth Health Services segment offers a diverse range of health services, including pharmacy benefits and care delivery solutions, catering to a broad customer base. Recent acquisitions and expansions in the health care sector have positioned The Cigna Group as a key player in the managed health care industry. Cons Regulatory changes in the health care industry could impact the company's operations and profitability. Intense competition in the managed health care sector may put pressure on The Cigna Group's market share and margins. Economic downturns or fluctuations in health care spending could affect the company's financial performance and growth trajectory. #22 - Boston ScientificNYSE:BSXStock Price: $67.24 (+$1.01)Market Cap: $99.35 billionP/E Ratio: 62.8Consensus Rating: Buy (18 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $66.62 (-0.9% Upside)Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Boston Scientific Stock Pros Boston Scientific Co. has shown consistent growth in revenue and earnings, indicating a strong financial performance. The company's stock price has been steadily increasing, reflecting positive investor sentiment and potential for further growth. Ongoing product innovation and development, such as the latest medical equipment offerings, can drive future profitability. Cons Market volatility and regulatory challenges in the medical equipment industry can impact Boston Scientific's stock performance. Intense competition from other healthcare companies may pressure margins and limit market share growth for Boston Scientific. Fluctuations in healthcare policies and reimbursement rates could affect the company's revenue streams and profitability. #23 - Gilead SciencesNASDAQ:GILDStock Price: $73.26 (-$0.43)Market Cap: $91.80 billionP/E Ratio: 16.3Dividend Yield: 4.18%Consensus Rating: Hold (5 Buy Ratings, 9 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $85.36 (16.5% Upside)Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc., and Tentarix Biotherapeutics Inc., as well as a partnership with Assembly Biosciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was incorporated in 1987 and is headquartered in Foster City, California. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Gilead Sciences Stock Pros Gilead Sciences has a diverse portfolio of products catering to various medical needs, including treatments for HIV/AIDS, viral hepatitis, oncology, and other serious diseases. The company has a strong history of collaboration agreements with reputable organizations in the biopharmaceutical industry, which can lead to innovative developments and market opportunities. Gilead Sciences' recent stock price performance has shown stability and potential growth, making it an attractive option for investors seeking long-term returns. Cons The biopharmaceutical industry is highly competitive and subject to regulatory challenges, which can impact Gilead Sciences' product development and market performance. Market volatility and economic uncertainties can affect the company's revenue streams and stock price, leading to potential risks for investors. While Gilead Sciences has a strong product portfolio, the success of new drug launches and treatments is not guaranteed, posing a risk to the company's financial performance. #24 - GSKNYSE:GSKStock Price: $42.15 (-$0.04)Market Cap: $86.84 billionP/E Ratio: 14.0Dividend Yield: 3.78%Consensus Rating: Hold (3 Buy Ratings, 1 Hold Ratings, 1 Sell Ratings)Consensus Price Target: N/AGSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of GSK Stock Pros GSK plc has shown consistent growth in institutional investments, indicating confidence from major financial entities like Anchor Investment Management LLC and Mercer Global Advisors Inc. ADV. Recent stock performance shows stability with a market cap of $88.80 billion, a price-to-earnings ratio of 14.33, and a beta of 0.64, suggesting a strong position in the market. Analysts predict a positive outlook for GSK plc with an estimated earnings per share of 4.08 for the current fiscal year, indicating potential profitability. Cons Despite recent institutional investments, GSK plc faces competition in the pharmaceutical industry, which could impact its market share and revenue growth. The pharmaceutical sector is subject to regulatory challenges and pricing pressures, affecting GSK plc's profitability and market performance. Fluctuations in global economic conditions and healthcare policies may influence GSK plc's revenue streams and overall financial stability. #25 - HCA HealthcareNYSE:HCAStock Price: $327.18 (+$5.21)Market Cap: $85.16 billionP/E Ratio: 17.2Dividend Yield: 0.82%Consensus Rating: Moderate Buy (10 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $308.26 (-5.8% Upside)HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, it operates behavioral hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of HCA Healthcare Stock Pros HCA Healthcare reported strong earnings results, beating the consensus estimate, with a significant EPS of $5.90 for the quarter. The company had a robust revenue of $17.30 billion during the quarter, showcasing solid financial performance. Institutional investors have been increasing their stakes in HCA Healthcare, indicating confidence in the company's future growth potential. Cons While the company has shown strong financial performance, the stock price may already reflect this success, potentially limiting short-term gains. There could be regulatory risks associated with the healthcare industry, impacting the company's operations and profitability. Market volatility and economic uncertainties could affect the demand for healthcare services, impacting HCA Healthcare's revenue streams. #26 - ZoetisNYSE:ZTSStock Price: $170.67 (-$1.90)Market Cap: $79.01 billionP/E Ratio: 33.7Dividend Yield: 1.00%Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $224.33 (31.4% Upside)Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Zoetis Stock Pros Zoetis Inc. is a leading company in the animal health industry, with a strong focus on developing and commercializing medicines, vaccines, and diagnostic products for both livestock and companion animals. The company has a diverse product portfolio that includes parasiticides, vaccines, dermatology products, anti-infectives, and animal health diagnostics, catering to a wide range of animal health needs. Zoetis Inc. has a history of collaboration with other companies, such as Blacksmith Medicines, Inc., to innovate and develop novel antibiotics for animal health, showcasing a commitment to research and development. Cons While Zoetis Inc. operates in a stable industry, it is subject to regulatory challenges and competition from other pharmaceutical companies, which could impact its market position and profitability. Fluctuations in commodity prices, global economic conditions, and disease outbreaks among animals can influence Zoetis Inc.'s performance, leading to potential risks for investors. Investors should consider the current stock price of Zoetis Inc. and evaluate whether it aligns with their investment goals and risk tolerance, as market conditions can affect stock valuations. #27 - McKessonNYSE:MCKStock Price: $529.71 (-$3.93)Market Cap: $70.12 billionP/E Ratio: 24.0Dividend Yield: 0.46%Consensus Rating: Moderate Buy (10 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $522.21 (-1.4% Upside)McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment offers distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of McKesson Stock Pros McKesson's stock price has shown a consistent upward trend, indicating potential for capital appreciation. The company has a strong market cap of $66.33 billion, reflecting stability and size in the industry. McKesson's quarterly earnings results have consistently exceeded analyst estimates, demonstrating strong financial performance. Cons McKesson's P/E ratio of 22.87 may indicate the stock is currently overvalued compared to industry peers. The company's negative return on equity of 262.63% raises concerns about profitability and operational efficiency. McKesson's insider selling activity, such as CEO Brian S. Tyler selling shares, could signal lack of confidence in the company's future prospects. #28 - AetnaNYSE:AETStock Price: $212.70Market Cap: $69.64 billionP/E Ratio: 21.6Dividend Yield: 0.94%Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AAetna Inc. operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis. It also provides point-of-service, preferred provider organization, health maintenance organization, and indemnity benefit plans, as well as health savings accounts and consumer-directed health plans. In addition, this segment offers Medicare and Medicaid products and services, as well as other medical products, such as medical management and data analytics services, medical stop loss insurance, workers' compensation administrative services, and products that provide access to its provider networks in select geographies. The Group Insurance segment offers life insurance products, including group term life insurance, voluntary spouse and dependent term life insurance, group universal life insurance, and accidental death and dismemberment insurance; disability insurance products; and long-term care insurance products, which provide the benefits to cover the cost of care in private home settings, adult day care, assisted living, or nursing facilities. The Large Case Pensions segment manages various retirement products comprising pension and annuity products primarily for tax-qualified pension plans. The company provides its products and services to employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Aetna Inc. was founded in 1853 and is based in Hartford, Connecticut. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Aetna Stock Pros Aetna Inc. operates as a health care benefits company in the United States, providing a wide range of health care services and products, which can lead to stable revenue streams. The company offers Medicare and Medicaid products and services, tapping into government-sponsored healthcare programs that can provide consistent income. Aetna Inc. has a long history, being founded in 1853, indicating stability and experience in the healthcare industry. Cons Changes in healthcare regulations and policies can impact the company's operations and profitability, leading to uncertainties in the market. The competitive landscape in the healthcare industry is intense, with other major players vying for market share, potentially affecting Aetna Inc.'s growth prospects. Market volatility and economic uncertainties can influence the stock performance of Aetna Inc., posing risks to investors. #29 - Becton, Dickinson and CompanyNYSE:BDXStock Price: $237.70 (+$0.99)Market Cap: $68.39 billionP/E Ratio: 56.3Dividend Yield: 1.61%Consensus Rating: Moderate Buy (5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $279.17 (17.4% Upside)Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Becton, Dickinson and Company Stock Pros Becton, Dickinson and Company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional, providing diversified revenue streams. The company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products, catering to a wide range of healthcare needs. Recent positive developments in the company's product pipeline have shown promising growth potential, attracting investor interest. Cons Market competition in the healthcare sector is intense, leading to potential pricing pressures and challenges in maintaining market share. Regulatory changes and uncertainties in the healthcare industry could impact the company's operations and profitability. Fluctuations in raw material costs and supply chain disruptions may affect the company's production costs and margins. #30 - AllerganNYSE:AGNStock Price: $193.02Market Cap: $63.50 billionDividend Yield: 1.53%Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AAllergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Allergan Stock Pros Allergan plc is a well-established pharmaceutical company with a diverse portfolio of branded pharmaceuticals, devices, biologics, and surgical products. Recent developments in research and development have led to the creation of innovative and potentially lucrative products. The company has a strong track record of successful mergers and acquisitions, which have contributed to its growth and market presence. Cons While the company has a diverse product portfolio, it also faces intense competition in the pharmaceutical industry, which could impact its market share and profitability. Regulatory challenges and changes in healthcare policies could pose risks to Allergan plc's operations and financial performance. Investing in pharmaceutical companies involves inherent risks related to clinical trials, drug approvals, and market acceptance of new products. #31 - Edwards LifesciencesNYSE:EWStock Price: $92.86 (+$0.55)Market Cap: $55.51 billionP/E Ratio: 40.4Consensus Rating: Hold (9 Buy Ratings, 7 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $88.00 (-5.2% Upside)Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Edwards Lifesciences Stock Pros Edwards Lifesciences reported a strong revenue growth of 13.3% compared to the same quarter last year, indicating a positive trend in the company's financial performance. The company's net margin of 23.35% showcases efficient cost management and profitability, which can be attractive to investors seeking stable returns. Analysts forecast a growth in earnings per share for the current fiscal year, indicating potential for increased profitability and shareholder value. Cons Despite revenue growth, the company's stock price may already reflect the positive performance, potentially limiting short-term gains for investors. High insider selling activity in the past three months could raise concerns about management's long-term confidence in the company's growth trajectory. Market volatility and regulatory changes in the healthcare sector could impact Edwards Lifesciences Co.'s operations and financial results, leading to uncertainty for investors. #32 - ShireNASDAQ:SHPGStock Price: $179.20Market Cap: $54.71 billionP/E Ratio: 11.8Dividend Yield: 0.19%Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AShire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Shire Stock Pros Shire plc has shown consistent growth in its stock price, providing potential for capital appreciation. Recent positive developments in Shire's product pipeline, such as the launch of innovative pharmaceutical products, may lead to increased revenue and market share. Shire plc's strong financial position, with a healthy debt-to-equity ratio, indicates stability and potential for long-term growth. Cons Market volatility and regulatory challenges in the pharmaceutical industry could impact Shire plc's stock performance. Competition from other pharmaceutical companies introducing similar products may affect Shire plc's market share and profitability. Global economic conditions and currency fluctuations could pose risks to Shire plc's international operations and revenue streams. #33 - Express ScriptsNASDAQ:ESRXStock Price: $92.33Market Cap: $52.06 billionP/E Ratio: 13.0Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AExpress Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Express Scripts Stock Pros Express Scripts Holding has shown consistent growth in revenue and profitability over the past year, indicating a strong financial performance. The company's strategic partnerships and acquisitions have expanded its market reach and diversified its service offerings, potentially leading to increased market share. Express Scripts Holding's stock price has been steadily increasing, reflecting positive investor sentiment and potential for capital appreciation. Cons Despite recent growth, Express Scripts Holding faces regulatory challenges and uncertainties in the healthcare sector, which could impact its future performance. Competition in the pharmacy benefit management industry is intense, leading to pricing pressures and potential margin compression for Express Scripts Holding. Market volatility and macroeconomic factors could affect the company's financial results and stock price, posing risks to investors. #34 - DexComNASDAQ:DXCMStock Price: $134.72 (+$4.26)Market Cap: $50.29 billionP/E Ratio: 102.8Consensus Rating: Moderate Buy (12 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $136.67 (1.4% Upside)DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of DexCom Stock Pros DexCom's stock price has shown consistent growth over the past year, indicating positive investor sentiment and potential for further appreciation. The company has a strong market position in the medical device industry, particularly in continuous glucose monitoring systems, which have a growing demand due to the increasing prevalence of diabetes. DexCom has a history of innovation and product development, leading to a competitive edge in the market and potential for revenue growth. Cons The medical device industry is highly regulated, and any changes in regulations or compliance requirements could impact DexCom's operations and financial performance. Competition in the continuous glucose monitoring market is intensifying, with new entrants and existing players introducing innovative products, posing a threat to DexCom's market share. Market volatility and economic uncertainties could affect DexCom's stock price, leading to potential fluctuations in investor returns. #35 - CencoraNYSE:CORStock Price: $239.31 (+$1.08)Market Cap: $47.52 billionP/E Ratio: 26.1Dividend Yield: 0.86%Consensus Rating: Moderate Buy (6 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $214.90 (-10.2% Upside)Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Cencora Stock Pros Cencora, Inc. has shown consistent growth in its U.S. Healthcare Solutions segment, distributing a wide range of pharmaceutical products and related services to various healthcare providers, indicating a strong market presence and potential for revenue generation. The company has attracted significant investments from asset management firms and institutional investors, reflecting confidence in its business model and growth prospects. Cencora, Inc. offers a diverse portfolio of services, including pharmacy management, clinical trial support, data analytics, and sales force services, catering to different segments of the healthcare industry and potentially increasing revenue streams. Cons The competitive landscape in the healthcare distribution industry is intense, with established players and regulatory challenges that could impact Cencora, Inc.'s market position and profitability. Dependency on external funding from institutional investors and hedge funds, with a significant portion of the company's stock owned by such entities, may lead to volatility in share prices and potential dilution of ownership for individual investors. Market uncertainties and regulatory changes in the pharmaceutical sector could affect Cencora, Inc.'s operations and financial performance, posing risks to investor returns. #36 - IQVIANYSE:IQVStock Price: $253.88 (+$1.17)Market Cap: $45.87 billionP/E Ratio: 34.8Consensus Rating: Moderate Buy (12 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $256.80 (1.2% Upside)IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of IQVIA Stock Pros IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry globally, offering diversified revenue streams. The company operates through three segments, providing a wide range of services to pharmaceutical, biotechnology, device and diagnostic, and consumer health companies, ensuring a broad customer base. IQVIA Holdings Inc. has a collaboration with argenx SE, indicating strategic partnerships that can lead to potential growth opportunities. Cons Market volatility and regulatory changes in the life sciences industry can impact the company's financial performance and growth prospects. Competition in the industry from other research and analytics firms may pose challenges to IQVIA Holdings Inc.'s market share and pricing power. External factors such as global economic conditions and geopolitical events can influence the demand for the company's services, leading to fluctuations in revenue. #37 - Takeda PharmaceuticalNYSE:TAKStock Price: $14.56 (+$0.09)Market Cap: $45.79 billionP/E Ratio: 22.1Dividend Yield: 3.61%Consensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $22.00 (51.1% Upside)Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Takeda Pharmaceutical Stock Pros Takeda Pharmaceutical has a diverse portfolio of pharmaceutical products in areas such as gastroenterology, rare diseases, oncology, and neuroscience, providing revenue stability and growth potential. The company has engaged in numerous collaborations and licensing agreements with various biotech and pharmaceutical companies, enhancing its research and development capabilities and potentially leading to innovative product offerings. Recent financial disclosures show that Takeda Pharmaceutical has a market capitalization of $46.11 billion, indicating a strong presence in the market and potential for further growth. Cons The pharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact Takeda Pharmaceutical's product development and market access. Despite collaborations and licensing agreements, there is inherent risk in research and development, with no guarantee of successful product launches or market acceptance. The company's PEG ratio of 3.28 and beta of 0.54 suggest potential overvaluation and sensitivity to market fluctuations, posing risks to investor returns. #38 - IDEXX LaboratoriesNASDAQ:IDXXStock Price: $529.81 (+$0.04)Market Cap: $44.02 billionP/E Ratio: 52.6Consensus Rating: Moderate Buy (6 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $591.50 (11.6% Upside)IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of IDEXX Laboratories Stock Pros Recent expansion into international markets, providing opportunities for growth and increased revenue. Strong focus on research and development, leading to innovative products that can drive competitive advantage. Diversified product portfolio catering to companion animal veterinary, livestock, poultry, dairy, and water testing markets, reducing dependency on a single market segment. Cons Market competition in the diagnostic substances industry may impact IDEXX Laboratories' market share and pricing power. Regulatory challenges in different regions could affect product approvals and market penetration. Dependency on the veterinary and livestock sectors, which are subject to economic fluctuations and external factors. #39 - SeagenNASDAQ:SGENStock Price: $228.74Market Cap: $42.93 billionConsensus Rating: Hold (0 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $204.00 (-10.8% Upside)Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Seagen Stock Pros Seagen Inc. has a diverse portfolio of innovative cancer therapies, including ADCETRIS, PADCEV, and TUKYSA, targeting different types of cancer, providing potential for revenue growth. Recent acquisition of Seagen Inc. shares by Hudson Bay Capital Management LP indicates investor confidence in the company's future prospects, potentially leading to positive stock performance. Seagen Inc. has collaboration agreements with reputable pharmaceutical companies like Takeda, Merck, and Genmab, enhancing its research capabilities and market reach. Cons Market volatility in the biotechnology sector can impact Seagen Inc.'s stock price, leading to potential fluctuations in investment returns. Regulatory challenges and uncertainties in the healthcare industry may affect the approval and commercial success of Seagen Inc.'s pipeline products, posing risks to investor returns. Competition from other biotech companies developing similar cancer therapies could impact Seagen Inc.'s market share and revenue potential, affecting investor confidence. #40 - HumanaNYSE:HUMStock Price: $347.19 (-$0.96)Market Cap: $42.01 billionP/E Ratio: 17.5Dividend Yield: 1.02%Consensus Rating: Moderate Buy (9 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $494.00 (42.3% Upside)Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Humana Stock Pros Humana's strong quarterly revenue growth of 17.9% year-over-year indicates a positive trend in the company's financial performance. Humana's return on equity of 19.44% showcases the company's ability to generate profit from shareholders' equity. Humana's dividend yield of 1.01% provides investors with a steady income stream, enhancing the total return on investment. Cons Humana's payout ratio of 17.86% indicates a significant portion of earnings being distributed as dividends, potentially limiting reinvestment for growth. Recent target price adjustments by analysts, such as Mizuho lowering the price target, may reflect concerns about future performance or valuation. Humana's stock price volatility could pose risks for short-term investors seeking stable returns. Make This $3 Trade the Instant the Opening Bell Rings (Ad)Since the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…See Why This $3.00 Stock Could Hit $15.00#41 - AlconNYSE:ALCStock Price: $84.14 (-$0.84)Market Cap: $41.90 billionP/E Ratio: 42.9Consensus Rating: Moderate Buy (11 Buy Ratings, 1 Hold Ratings, 2 Sell Ratings)Consensus Price Target: $90.49 (7.5% Upside)Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Alcon Stock Pros Alcon Inc. has recently launched the Clareon Presbyopia Correcting IOLs in India, showcasing a commitment to innovation in the intraocular lens technology market. The company's diverse product portfolio, including cataract products like the Centurion vision system and refractive surgery products like the WaveLight lasers, positions it well in the ophthalmic goods industry. Alcon Inc.'s strong presence in the global eye care market, offering a wide range of eye care products for professionals and patients worldwide, provides stability and growth potential for investors. Cons Market competition in the ophthalmic goods industry can pose challenges for Alcon Inc., impacting its market share and profitability. Fluctuations in the global healthcare market and regulatory changes may affect Alcon Inc.'s operations and financial performance, leading to uncertainties for investors. Investors should consider the potential risks associated with investing in a company that operates in the healthcare facilities subindustry, which can be influenced by factors like healthcare policies and reimbursement rates. #42 - GE HealthCare TechnologiesNASDAQ:GEHCStock Price: $90.61 (+$1.20)Market Cap: $40.71 billionP/E Ratio: 30.0Dividend Yield: 0.13%Consensus Rating: Moderate Buy (7 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $88.73 (-2.1% Upside)GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of GE HealthCare Technologies Stock Pros GE HealthCare Technologies Inc. has shown consistent revenue growth, with a 5.3% increase in revenue compared to the same quarter last year. The company reported a strong net margin of 8.02% and a return on equity of 25.58%, indicating efficient operations and profitability. Analysts have given GE HealthCare Technologies Inc. a "Moderate Buy" rating with an average target price of $88.83, suggesting potential upside. Cons Despite positive analyst ratings, there are still some hold ratings on the stock, indicating a level of uncertainty in the market. The company's payout ratio is relatively low at 3.97%, which may not be attractive to income-focused investors seeking higher dividend yields. GE HealthCare Technologies Inc. operates in a competitive industry with rapidly evolving technology, which could pose challenges for maintaining market share. #43 - CenteneNYSE:CNCStock Price: $77.02 (+$1.55)Market Cap: $40.37 billionP/E Ratio: 15.7Consensus Rating: Moderate Buy (6 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $85.15 (10.6% Upside)Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support. This segment also provides healthcare products. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. It also operates clinical healthcare and pharmacies, as well as offers dental services. In addition, the company engages in the government contracts business under the TRICARE program and other healthcare related government contracts. It provides services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in Saint Louis, Missouri. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Centene Stock Pros Centene Corporation operates in the healthcare industry, specifically in managed health care, which is known for its stability and consistent demand. With a focus on providing programs and services to under-insured and uninsured families, Centene has a broad customer base that is likely to grow over time. Centene's diverse segments, including Medicaid, Medicare, Commercial, and others, provide a well-rounded portfolio that can withstand market fluctuations. Cons Centene's stock price may be subject to fluctuations due to regulatory changes in the healthcare industry, impacting investor sentiment and stock performance. The competitive landscape in the managed health care industry is intense, with other major players vying for market share, potentially affecting Centene's profitability and growth trajectory. Uncertainties surrounding government healthcare policies and regulations could pose risks to Centene's operations and financial performance in the future. #44 - Alexion PharmaceuticalsNASDAQ:ALXNStock Price: $182.50Market Cap: $40.34 billionP/E Ratio: 59.6Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AAlexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Alexion Pharmaceuticals Stock Pros Alexion Pharmaceuticals, Inc. has a strong product portfolio including ULTOMIRIS and SOLIRIS, which are used to treat various rare diseases, providing a diversified revenue stream. The company is actively involved in developing new therapies such as ALXN1210 (Intravenous) and ALXN1210 (Subcutaneous) for multiple indications, expanding its market potential. Recent positive clinical trial results for ALXN1840 in Phase III for Wilson disease indicate potential future revenue growth. Cons The biopharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact the company's product development and market access. Dependency on a few key products like ULTOMIRIS and SOLIRIS for a significant portion of revenue poses a risk in case of market changes or competition. Ongoing clinical trials for new therapies like ALXN1820 and ALXN1720 are in early stages, with uncertainties regarding successful outcomes and market acceptance. #45 - ModernaNASDAQ:MRNAStock Price: $104.26 (+$0.41)Market Cap: $39.68 billionConsensus Rating: Hold (5 Buy Ratings, 8 Hold Ratings, 2 Sell Ratings)Consensus Price Target: $129.82 (24.5% Upside)Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Moderna Stock Pros Moderna, Inc. is a leading biotechnology company that focuses on developing messenger RNA therapeutics and vaccines for various diseases, including COVID-19. The company has a diverse pipeline of products targeting infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases, providing potential for revenue growth. Moderna has established strategic partnerships with key players in the industry, such as AstraZeneca, Merck, and the Bill & Melinda Gates Foundation, enhancing its research capabilities and market reach. Cons Market competition in the biotechnology sector is intense, with other companies also developing mRNA-based therapies and vaccines, potentially impacting Moderna's market share and profitability. Regulatory uncertainties and challenges in obtaining approvals for new products could lead to delays in commercialization and revenue generation for Moderna. Investing in biotechnology companies like Moderna carries inherent risks due to the complex nature of drug development, including clinical trial failures, adverse effects, and regulatory setbacks. #46 - HaleonNYSE:HLNStock Price: $8.12 (-$0.19)Market Cap: $38.37 billionP/E Ratio: 29.0Dividend Yield: 2.56%Consensus Rating: Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AHaleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands includes Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Weybridge, the United Kingdom. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Haleon Stock Pros Haleon plc has a diverse portfolio of consumer healthcare products, including well-known brands like Advil, Sensodyne, and Centrum, which have strong market presence and consumer trust. Recent investments by institutional investors like Optiver Holding B.V. indicate confidence in the company's growth potential, which can positively impact the stock price. The company's global presence across multiple regions provides geographical diversification, reducing risks associated with regional economic fluctuations. Cons Despite positive analyst ratings, there are only two hold ratings on the stock, which may indicate some uncertainty or caution among analysts regarding the company's future performance. The stock price of Haleon plc has shown minimal movement recently, with a 50-day moving average price close to the 200-day moving average, suggesting limited short-term price momentum. Competition in the consumer healthcare products industry is intense, with other major players constantly innovating and introducing new products, posing a challenge to Haleon plc's market share and growth prospects. #47 - BiogenNASDAQ:BIIBStock Price: $219.40 (+$0.09)Market Cap: $31.88 billionP/E Ratio: 27.5Consensus Rating: Moderate Buy (19 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $305.68 (39.3% Upside)Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Biogen Stock Pros Biogen Inc. offers a diverse range of therapies for treating neurological and neurodegenerative diseases, including the latest versions like TECFIDERA, VUMERITY, and ADUHELM, catering to a growing market demand. The company has a strong pipeline of products under development for various conditions such as Alzheimer's disease, MS, and neuromuscular disorders, indicating potential future revenue growth. Recent collaborations and license agreements with prominent pharmaceutical companies like Genentech and Samsung Bioepis enhance Biogen's research capabilities and market reach. Cons Biogen Inc. faces competition from other pharmaceutical companies in the development and commercialization of treatments for neurological and neurodegenerative diseases, which could impact market share and profitability. The company's success heavily relies on the approval and market acceptance of its pipeline products, with any setbacks in clinical trials or regulatory processes posing risks to financial performance. Market volatility and regulatory changes in the biotechnology industry can affect Biogen's stock price, leading to potential fluctuations in investor returns. #48 - West Pharmaceutical ServicesNYSE:WSTStock Price: $395.72 (+$8.10)Market Cap: $28.38 billionP/E Ratio: 50.2Dividend Yield: 0.21%Consensus Rating: Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $435.20 (10.0% Upside)West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of West Pharmaceutical Services Stock Pros West Pharmaceutical Services, Inc. operates in two segments, Proprietary Products and Contract-Manufactured Products, providing diversified revenue streams. The company offers drug containment solutions like Crystal Zenith, a cyclic olefin polymer, which is innovative and caters to the needs of pharmaceutical companies. West Pharmaceutical Services, Inc. provides integrated solutions including analytical lab services, regulatory expertise, and after-sales technical support, enhancing customer satisfaction. Cons The healthcare industry, where West Pharmaceutical Services operates, can be subject to regulatory changes and market uncertainties, impacting the company's performance. Competition in the healthcare supplies subindustry is intense, potentially affecting the company's market share and profitability. Global economic conditions and geopolitical factors can influence the demand for healthcare products, posing risks to West Pharmaceutical Services' revenue. #49 - ResMedNYSE:RMDStock Price: $191.05 (+$1.00)Market Cap: $27.95 billionP/E Ratio: 31.6Dividend Yield: 1.01%Consensus Rating: Moderate Buy (7 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $196.30 (2.7% Upside)ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of ResMed Stock Pros ResMed's consistent revenue growth over the past few quarters showcases its strong market position and potential for future profitability. The company's focus on developing innovative medical devices and cloud-based software applications keeps it at the forefront of technological advancements in healthcare. ResMed's expansion into different segments like Sleep and Respiratory Care, and Software as a Service diversifies its revenue streams and reduces dependency on a single market. Cons ResMed faces competition from other established companies in the medical instruments and supplies industry, which could impact its market share and profitability. The company's reliance on technological advancements and regulatory approvals for its products exposes it to risks associated with changing industry standards and regulations. Fluctuations in healthcare policies and reimbursement rates could affect ResMed's financial performance and growth prospects. #50 - CernerNASDAQ:CERNStock Price: $94.92Market Cap: $27.92 billionP/E Ratio: 47.7Dividend Yield: 1.14%Consensus Rating: N/A (0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/ACerner Corporation, together with its subsidiaries, provides health care information technology solutions and tech-enabled services in the United States and internationally. It offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers. The company also provides HealtheIntent platform, a cloud-based platform to aggregate, transform, and reconcile data across the continuum of care; and CareAware, an EHR agnostic platform that facilitates connectivity of health care devices to EHRs. In addition, it offers a portfolio of clinical and financial healthcare information technology solutions, as well as departmental and care coordination solutions. Further, the company provides tech-enabled services, such as implementation and training, remote hosting, application management, revenue cycle, support and maintenance, health care data analysis, real-world evidence, clinical process optimization, transaction processing, employer health centers, and data-driven services; and complementary hardware and devices for third parties. It serves integrated delivery networks, physician groups and networks, managed care organizations, hospitals, medical centers, free-standing reference laboratories, home health agencies, blood banks, imaging centers, pharmacies, pharmaceutical manufacturers, employers, governments, and public health organizations. The company was founded in 1979 and is headquartered in North Kansas City, Missouri. A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. Pros and Cons of Cerner Stock Pros Cerner is a leading supplier of health care information technology solutions, health care devices, and remote hosting services, positioning it well in the growing health tech sector. The company recently announced plans to acquire Change Healthcare for $13 billion, which is expected to enhance its health care technology and data analytics business, potentially leading to increased revenue and market share. With a strong market share in the electronic health record space, Cerner has significant growth potential as healthcare facilities increase their IT spending post-pandemic. Cons While Cerner has growth potential, the competitive landscape in the health tech industry is intense, with other major players vying for market share and innovation. Recent Medical HeadlinesUnitedHealth says it has made progress on recovering from a massive cyberattackMarch 18, 2024 5:08 PMUnitedHealth Group is testing software for submitting medical claims as it continues to recover from a cyberattack that disrupted care billing systemsSouth Korea will suspend licenses of 2 senior doctors in first punishment for doctors' walkoutsMarch 18, 2024 7:45 AMSouth Korean authorities will suspend the licenses of two senior doctors for allegedly inciting the weekslong walkouts by medical interns and residents that have disrupted hospital operationsFrom Frenchies to rescue cats, New York's trauma center for animals takes the most complex casesMarch 17, 2024 9:41 AMThe Schwarzman Animal Medical Center in New York City is one of a handful of veterinary hospitals across the country that is equipped to handle the most complicated casesAdobe, Ulta Beauty fall; Madrigal, Intuitive Surgical rise, Friday, 3/15/2024March 15, 2024 12:17 PMStocks that traded heavily or had substantial price changes on Friday: Adobe, Ulta Beauty fall; Madrigal, Intuitive Surgical riseEPA tightens limits on a chemical used to sterilize medical equipment, citing cancer riskMarch 14, 2024 1:30 PMThe Environmental Protection Agency is imposing stricter limits on a chemical used to sterilize medical equipment after finding a higher-than-expected cancer risk at facilities that use ethylene oxide to clean billions of devices including catheters and syringesMore Medical Headlines Top HeadlinesMarch 14, 2024 1:36 PMDefense Contractor Stocks Explained, Plus Investment GuideMarch 14, 2024 7:39 AM$5 Billion Boost for Taiwan Semiconductor Aids Nvidia ExpansionMarch 14, 2024 6:30 AM4 Oversold Large Cap Stocks Yielding High DividendsMarch 15, 2024 7:12 AMIs it Time to Buy These 5 Oversold Stocks?March 14, 2024 1:17 PMOracle's AI Cloud Demand Fuels Profitability SurgeMarch 18, 2024 6:15 AM3 Large-Cap Stocks Buying Back Shares AggressivelyMarch 14, 2024 12:39 PMUnlock the Secrets: Navigate the Crypto vs. Stocks Investing MazeAll Headlines (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Health Care Stocks Explained: Why You Might Want to InvestWritten by Melissa BrockUpdated August 23, 2023Healthcare Stocks and InflationAre Healthcare Stocks a Good Investment?When Do Healthcare Stocks Do Well?Healthcare Stock Share PerformanceTop Health Care Stocks ListUnitedHealth Group Inc. (NYSE: UNH)Johnson & Johnson (NYSE: JNJ)Eli Lilly and Company (NYSE: LLY)How to Invest in Health Care StocksStep 1: Check into metrics. Step 2: Open a brokerage account.Step 3: Buy the number of shares you want.Health Care Stock ETFsDo certain sectors seem about as appetizing as eating a soggy Slim Jim? The last thing you want to do is sink your money into a sector that has no upward mobility. It's wise to be careful, particularly during these inflationary times. But what about investing in the health care sector? It's worth digging into health care stocks because of their ability to transcend what's happening in the economy. In this article, we'll take a look at healthcare stocks during inflationary times, why a particular healthcare stock may make a good investment, when these particular stocks do well, the stock performance of some top healthcare stocks and how to invest in these particular stocks. We'll also help you put some health care stocks on your to-research list. Let's get started. Healthcare Stocks and Inflation Between the start of 1991 and the end of 2019, inflation on a year-over-year basis averaged about 2.3% a month and only went over 5% a handful of times. Not so over the past two years. The Consumer Price Index for All Urban Consumers did not change in July 2022 after rising 1.3% in June, according to the U.S. Bureau of Labor Statistics. The all items index increased 8.5% over the past year. A quick summary in July 2022: The gasoline index fell 7.7% in July The energy index fell 4.6% The food index increased 1.1% The food at home index rose 1.3% The index for all items (except for food and energy) rose 0.3% Some indexes increased, according to the Bureau of Labor Statistics (shelter, medical care, motor vehicle insurance, household furnishings and operations, new vehicles and recreation) and some declined (airfare, used cars and trucks, communication and apparel). Despite the fact that inflation has been low over the past decades, healthcare stocks remain one of the most important inflation mediators due to the worldwide aging population, advanced technologies and breakthroughs in clinical trials also encourage success in the sector. Healthcare has been known as one of the best defensive sectors because they have typically been unchanged due to economic demands. Are Healthcare Stocks a Good Investment? As with anything else, it's important to evaluate a wide variety of stock fundamentals before you invest. However, in general, it's possible to bank on health care companies because they typically provide returns in a wide variety of markets. The general public always needs doctors and insurance companies, and the healthcare sector can help change the tide of your overall investment portfolio. It's no secret that the pandemic propelled healthcare stocks further, helping people get the products and services they needed. You'll also likely find cheap healthcare stocks and fat dividends that come along with them as well. When Do Healthcare Stocks Do Well? Shares of U.S. healthcare companies can do well in both good and poor economic times compared to other typically popular defensive sectors. If you're curious about healthcare stocks in general, you can take a look at the healthcare index (SPXHC). The S&P 500 sectors have ebbed and flowed, including health care. Energy (SPNY) as well as value stocks (IVX) increased. Healthcare stocks respond well in a few specific cases, including due to the aging population and Baby Boomers, people living with long-term diseases, epidemics, advances in technology, global and personalized medicine and other factors, according to a Reuters article. Investing in healthcare stocks can provide excellent returns, but many factors can affect stock prices. Certain downsides to healthcare stocks may impinge on their ability to deliver returns to investors. The roadblocks that could cause healthcare stocks to do well include a single-payer system, the uninsured, cost roadblocks and consumerism. Healthcare Stock Share Performance U.S. healthcare spending grew 9.7% in 2020, at a rate of $4.1 trillion or $12,530 per person, according to the American Medical Association. U.S. spending on health care declined for the first time in 60 years in Q1 of 2022 and fell 1.7% year over year as healthcare prices fell relative to inflation, according to a recent Altarum report. According to Modern Healthcare, healthcare prices in general should rise by 3.6% in 2022 and boost overall healthcare spending growth 4.6% to $4.5 trillion. Prices grew: 2.7% in 2021 3.1% in 2020 1.1% in 2019 A recent AHA report showed hospitals have experienced surging costs in items and resources required to care for patients since the start of the COVID-19 pandemic. Expenses per patient rose as follows: Labor: 19.1% between 2019 and 2021 Travel nurse costs: 39% of nurse labor expenses by January 2022 Supply costs: 21% per patient Median drug costs: 37% per patient Intensive care unit medical supply costs: 32% per patient These facts and figures can help health care stock performance go up and/or down. It's a good idea to keep them in mind as you evaluate each stock on an individual basis. Top Health Care Stocks List Let's take a look at three top health care stock examples in order to help you choose the right investments for your portfolio. UnitedHealth Group Inc. (NYSE: UNH) UnitedHealth Group Inc. (NYSE: UNH), a diversified health care company, offers a wide range of services, including: Consumer-oriented health benefit plans Services for national, public sector and mid-sized employers Services small businesses Preventive, acute health care and chronic disease services Medicaid plans Children's health insurance and health care programs Health and dental benefits Hospital and clinical services Networks of care provider specialists Software and information products Advisory consulting arrangements Managed services outsourcing contracts Pharmacy care services and programs In Q2, UnitedHealth Group showed revenues of $80.3 billion, which grew 13% year over year. Earnings from operations were $7.1 billion, a growth of 19% since last year. Cash flows from operations were $6.9 billion, 1.3 times net income. Johnson & Johnson (NYSE: JNJ) Johnson & Johnson (NYSE: JNJ) researches, develops and manufactures products under a wide variety of brands, including JOHNSON'S, AVEENO, LISTERINE, CLEAN & CLEAR, NEUTROGENA, OGX, TYLENOL, SUDAFED, BENADRYL, ZYRTEC, MOTRIN IB, NICORETTE, PEPCID, STAYFREE, CAREFREE, BAND-AID and NEOSPORIN. The company creates treatments for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, psoriasis, HIV/AIDS and COVID-19, mood disorders, neurodegenerative disorders, schizophrenia, cardiovascular diseases and more. Total sales for Johnson & Johnson grew 3% to $24 billion with operational growth of 8% and adjusted operational growth of 8.1%. Eli Lilly and Company (NYSE: LLY) Eli Lilly and Company (NYSE: LLY) develops and sells pharmaceuticals worldwide including the following major brands: Basaglar Humalog Humulin Jardiance Trajenta Trulicity Cyramza Erbitux Retevmo Cymbalta Zyprexa Cialis Lilly's revenue in Q2 2022 decreased 4%. Total revenue grew 6%, including the U.S. approval and launch of Mounjaro for type 2 diabetes. Trulicity, Verzenio, Jardiance, Taltz, Retevmo, Mounjaro, Emgality, Olumiant, Tyvyt and Cyramza grew 20% and represented 67% of revenue in Q2 2022. EPS decreased 31% to $1.05 on a reported basis and decreased 32% to $1.25 on a non-GAAP basis. The FDA approved Mounjaro® (tirzepatide) for adults with type 2 diabetes. Lilly and Incyte's Olumiant® (baricitinib) also received approval, and so did Olumiant for certain patients with COVID-19. The company also announced plans to invest $2.1 billion in two new Indiana manufacturing sites. How to Invest in Health Care Stocks Let's take a comprehensive look at how you may want to approach investing in healthcare stocks. Step 1: Check into metrics. Digging into the metrics of individual stocks can help you decide how to choose investments you may want to invest in. Consider looking at dividend yield, earnings per share and price-to-earnings ratio. There are other metrics you may want to look at, but we'll go over the definition of these items. Dividend yield: The dividend yield tells you how much the company yields in dividends. Analyze the dividends per share divided by the current share price. High-yield dividends can be risky, so determine whether competitors have a much higher dividend yield than the stocks you're considering. Earnings per share (EPS): The earnings per share (EPS) shows how many outstanding shares of stock a company has. You can calculate it by finding out a company's quarterly or annual net income and dividing by the number of outstanding shares of stock it owns. Price-to-earnings (P/E) ratio: The price-to-earnings (P/E) ratio helps show you whether a company is fairly valued. To find the P/E ratio, you can divide a company's share price by its earnings per share. Step 2: Open a brokerage account. Do you have a brokerage account? If not, open a brokerage account and fund it. You can choose from three types of brokerages, including online brokers, discount brokers and full-service brokers. Let's take a look at the definition of these three options: Online brokers: Online brokers offer an online option for investing. You can typically depend on speed, ease of use and low commissions with an online brokerage. Discount broker: A discount broker performs buy and sell orders at lower commission rate compared to full-service brokers. Full-service broker: Full-service brokerages provide a wide range of investment services, including tax tips, research and investing on their behalf, to name a few. No matter which direction you prefer, it's a good idea to look at the fees involved, platforms available to you and more. You want to be sure you choose the right option for your needs. Step 3: Buy the number of shares you want. Choose the number of shares you want to purchase and hit the "buy" button. Choose the right investments that meet your specific goals and investment timeline. Consider investing on a monthly basis in order to build on compound interest over the long term. Health Care Stock ETFs The healthcare sector offers a wide range of large and small companies to invest in. However, you can invest in more than just stocks. You can invest in mutual funds and exchange-traded funds (ETFs) to add diversification to your holdings. An ETF works like a mutual fund — a pooled investment — but you can buy and sell at any time during the trading day, like a stock. Here is a list of healthcare ETFs you may want to consider investing in: Health Care Select Sector SPDR ETF (NYSEARCA: XLV) Invesco S&P 500 Equal Weight Health Care ETF (NYSEARCA: RYH) iShares Global Healthcare ETF (NYSEARCA: IXJ) iShares Nasdaq Biotechnology ETF (NYSEARCA: IBB) SPDR S&P Health Care Equipment ETF (NYSEARCA: XHE) State Street Global Advisors' Health Care Select Sector SPDR Fund (NYSEARCA: XLV) Vanguard Health Care Index Fund ETF (NYSEARCA: VHT) Still interested in other options? Learn more about cancer stocks. About Melissa Brockbrockm1@central.eduAssociate Editor & Contributing AuthorDividend Stocks, RetirementExperienceMelissa Brock has been an associate editor & contributing writer for MarketBeat since 2021.While working in college admission, Melissa Brock pursued a freelance writing and editing career. She currently works as a full-time freelance writer and financial editor covering higher education, investing, personal finance, mortgages, college savings, insurance, and more. She developed her website, College Money Tips, to help families navigate the college journey. She connects with a wide-reaching audience through her site, through an upcoming digital course, and the myriad of publications for which she writes. Melissa graduated summa cum laude with a bachelor of arts in communication studies with minors in psychology and Spanish from Central College. She's a longtime member of the National Association of College Admission Counseling (NACAC). More Stock Ideas from MarketBeat Stock Lists: 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks: Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange: NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEMKT Stocks NYSEARCA Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas: Insider Selling of Amazon Spikes in Q1, but it's Not Time to Sell Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off 2 Dollar Stores Taking Different Paths to Profitability S&P 500 Valuations Hit New Highs: Anticipating a Market Pullback? MarketBeat Week in Review – 3/11 – 3/15 These 3 Stocks Just Entered Overbought Territory Adobe Stock Reaches Turning Point as Market Outlook Resets Analysts Lead These Markets: The Most Upgraded Stocks in Q1 Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.